— Know what they know.
Not Investment Advice
Also trades as: AJANTPHARM.BO (BSE) · $vol 0M

AJANTPHARM.NS NSE

Ajanta Pharma Limited
1W: +1.2% 1M: +2.2% 3M: +7.7% YTD: +23.9% 1Y: +35.5% 3Y: +111.8% 5Y: +150.5%
₹3,512.50 ($36.48)
-68.50 (-1.91%)
 
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Buy · Power 57 · ₹448.0B mcap · 42M float · 0.270% daily turnover

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

B-
Oct 05, 2026
DCF
5
ROE
5
ROA
1
D/E
1
P/E
1
P/B
1
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. AJANTPHARM.NS receives an overall rating of B-. Strongest factors: DCF (5/5), ROE (5/5). Areas of concern: ROA (1/5), D/E (1/5), P/E (1/5), P/B (1/5).
Rating Change History
DateFromTo
2026-10-01 C+ B-
2026-09-25 B- C+
2026-09-23 C+ B-
2026-09-17 B- C+
2026-08-17 C B-
2026-08-03 A- C
2026-05-06 C A-
2026-02-01 A- C

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 69 Grade A+
Profitability
94
Balance Sheet
90
Earnings Quality
64
Growth
66
Value
48
Momentum
80
Safety
100
Cash Flow
53
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. AJANTPHARM.NS scores highest in Safety (100/100) and lowest in Value (48/100). An overall grade of A+ places AJANTPHARM.NS among the highest-quality companies in its peer group.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
16.00
Safe Zone
Piotroski F-Score
5/9
✓ ✓ ✓ ✗ ✗ ✗ ✗ ✓ ✓
Beneish M-Score
-1.81
Unlikely Manipulator
Ohlson O-Score
-11.90
Bankruptcy prob: 0.0%
Low Risk
Credit Rating
AA+
Score: 94.7/100
Trend: Stable
Earnings Quality
75/100
OCF/NI: 0.94x
Accruals: 1.2%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. AJANTPHARM.NS scores 16.00, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. AJANTPHARM.NS scores 5/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. AJANTPHARM.NS's score of -1.81 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. AJANTPHARM.NS's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. AJANTPHARM.NS receives an estimated rating of AA+ (score: 94.7/100), with a stable trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). AJANTPHARM.NS's score of 75/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
38.92x
PEG
1.75x
P/S
7.65x
P/B
9.76x
P/FCF
61.70x
P/OCF
35.34x
EV/EBITDA
22.10x
EV/Revenue
6.35x
EV/EBIT
24.85x
EV/FCF
60.99x
Earnings Yield
3.01%
FCF Yield
1.62%
Shareholder Yield
1.25%
Graham Number
$830.25
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 38.9x earnings, AJANTPHARM.NS commands a growth premium. Graham's intrinsic value formula yields $830.25 per share, 332% below the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.767
NI / EBT
×
Interest Burden
0.988
EBT / EBIT
×
EBIT Margin
0.256
EBIT / Rev
×
Asset Turnover
0.976
Rev / Assets
×
Equity Multiplier
1.343
Assets / Equity
=
ROE
25.4%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. AJANTPHARM.NS's ROE of 25.4% is driven by Asset Turnover (0.976), indicating efficient use of assets to generate revenue.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
15.00%
Fair P/E
38.50x
Intrinsic Value
$3254.62
Price/Value
0.86x
Margin of Safety
13.81%
Premium
-13.81%
Assessment
Neutral
Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with AJANTPHARM.NS's realized 15.0% 3-year EPS CAGR, capped at 15% — demonstrated performance rather than forecasts, held to a rate companies have historically sustained. AJANTPHARM.NS actually compounded EPS at 21.9% over three years; the model uses 15%, the highest rate it will extrapolate — of 4,457 company-quarters that grew faster than 200%, none sustained it over the following seven years. AJANTPHARM.NS trades at a -14% premium to its adjusted intrinsic value of $3254.62, suggesting the market is pricing in future growth beyond what historical earnings support. The adjusted fair P/E of 38.5x compares to the current market P/E of 38.9x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$3581.00
Median 1Y
$4353.00
5th Pctile
$2634.33
95th Pctile
$7188.63
Ann. Volatility
30.4%
25th–75th percentile 5th–95th percentile Median path Historical
All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
ROE 24.3% 22.5% 23.0% 22.8% 22.8% 19.4% 17.7% 17.7% 18.7% 18.6% 20.8% 23.5% 24.6% 24.4% 25.1% 25.0% 25.3% 24.4% 25.4% 25.4% 25.39%
ROA 19.2% 18.2% 18.6% 18.2% 18.2% 15.8% 14.5% 13.5% 14.2% 14.9% 16.6% 17.5% 18.3% 19.0% 19.5% 19.1% 19.3% 18.6% 19.4% 18.9% 18.91%
ROIC 24.9% 23.8% 23.8% 21.4% 21.4% 20.5% 19.3% 22.0% 23.6% 20.9% 23.2% 24.2% 30.1% 41.5% 42.0% 40.9% 45.3% 34.0% 43.3% 45.6% 45.62%
ROCE 29.5% 26.6% 27.0% 27.0% 27.0% 23.1% 21.4% 21.2% 22.6% 24.0% 27.4% 30.0% 31.4% 30.7% 31.3% 30.1% 30.4% 28.2% 29.2% 29.4% 29.41%
Gross Margin 77.1% 73.8% 77.4% 63.9% 70.5% 72.3% 72.3% 72.7% 75.3% 75.1% 73.4% 49.5% 76.6% 77.9% 77.5% 69.4% 78.8% 50.0% 79.2% 78.6% 78.56%
Operating Margin 25.3% 26.1% 24.8% 22.1% 20.0% 21.7% 17.6% 17.4% 24.3% 25.0% 26.0% 23.2% 43.9% 53.1% 24.9% 25.6% 52.4% 24.1% 52.0% 51.4% 51.40%
Net Margin 23.2% 22.1% 22.9% 18.6% 18.4% 16.7% 13.8% 13.9% 20.4% 19.0% 19.0% 19.2% 21.5% 18.2% 20.3% 20.3% 19.6% 19.2% 19.9% 18.8% 18.76%
EBITDA Margin 33.8% 33.0% 31.5% 29.0% 26.8% 25.2% 21.0% 21.1% 29.7% 30.3% 29.6% 29.8% 31.2% 27.9% 30.6% 28.4% 29.0% 28.6% 29.6% 27.8% 27.77%
FCF Margin 7.2% 8.3% 9.6% 9.3% 8.8% 7.6% 6.4% 6.3% 5.2% 5.1% 5.0% 8.6% 10.4% 12.1% 14.0% 14.9% 15.5% 14.0% 14.4% 10.4% 10.42%
OCF Margin 12.7% 13.0% 13.6% 13.2% 12.3% 9.9% 7.4% 7.3% 5.2% 5.1% 5.0% 9.5% 12.2% 14.6% 17.3% 19.1% 20.5% 21.6% 22.4% 18.2% 18.19%
ROE 3Y Avg snapshot only 23.50%
ROE 5Y Avg snapshot only 21.94%
ROA 3Y Avg snapshot only 17.70%
ROIC 3Y Avg snapshot only 29.73%
ROIC Economic snapshot only 40.20%
Cash ROA snapshot only 16.11%
Cash ROIC snapshot only 24.05%
CROIC snapshot only 13.78%
NOPAT Margin snapshot only 34.49%
Pretax Margin snapshot only 25.26%
R&D / Revenue snapshot only 1.16%
SGA / Revenue snapshot only 16.58%
SBC / Revenue snapshot only 0.05%
Valuation
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
P/E Ratio 26.07 26.63 25.71 20.97 21.25 23.16 24.24 24.93 28.86 33.28 34.57 33.75 33.04 44.97 40.46 35.19 34.21 30.54 34.10 33.18 38.919
P/S Ratio 6.06 6.07 5.82 4.55 4.35 4.41 4.07 3.92 4.70 5.63 6.30 6.54 6.51 8.76 8.02 7.06 6.70 6.05 6.73 6.43 7.647
P/B Ratio 5.92 5.59 5.52 4.58 4.64 4.33 4.15 4.33 5.29 6.31 7.30 7.72 7.91 10.70 9.88 8.55 8.39 6.89 8.02 7.74 9.757
P/FCF 84.20 73.02 60.93 49.19 49.55 57.80 63.48 62.24 90.33 109.52 125.57 76.42 62.37 72.47 57.42 47.33 43.23 43.21 46.75 61.70 61.699
P/OCF 47.50 46.63 42.81 34.56 35.34 44.58 54.82 53.75 90.33 109.52 125.57 69.11 53.37 59.87 46.27 36.89 32.76 28.09 30.03 35.34 35.336
EV/EBITDA 16.69 17.29 16.78 14.01 14.19 15.16 15.42 15.71 18.41 21.40 22.13 21.58 21.20 29.08 26.33 23.50 22.73 20.29 22.79 22.10 22.105
EV/Revenue 5.94 5.89 5.64 4.46 4.26 4.24 3.91 3.70 4.49 5.51 6.19 6.44 6.41 8.61 7.86 6.94 6.59 5.91 6.59 6.35 6.352
EV/EBIT 18.85 19.56 19.00 15.92 16.14 17.40 17.89 18.44 21.46 24.66 25.11 24.19 23.66 32.42 29.34 26.30 25.54 22.84 25.69 24.85 24.851
EV/FCF 82.55 70.83 59.07 48.20 48.56 55.62 60.97 58.81 86.26 107.28 123.36 75.24 61.43 71.16 56.30 46.50 42.46 42.20 45.81 60.99 60.987
Earnings Yield 3.8% 3.8% 3.9% 4.8% 4.7% 4.3% 4.1% 4.0% 3.5% 3.0% 2.9% 3.0% 3.0% 2.2% 2.5% 2.8% 2.9% 3.3% 2.9% 3.0% 3.01%
FCF Yield 1.2% 1.4% 1.6% 2.0% 2.0% 1.7% 1.6% 1.6% 1.1% 0.9% 0.8% 1.3% 1.6% 1.4% 1.7% 2.1% 2.3% 2.3% 2.1% 1.6% 1.62%
PEG Ratio snapshot only 1.755
Price/Tangible Book snapshot only 7.812
EV/OCF snapshot only 34.928
EV/Gross Profit snapshot only 8.860
Acquirers Multiple snapshot only 14.116
Shareholder Yield snapshot only 1.25%
Graham Number snapshot only $830.25
Leverage & Solvency
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Current Ratio 3.13 4.11 4.11 3.50 3.50 3.76 3.76 2.49 2.49 3.21 3.21 3.05 3.05 3.07 3.07 2.85 2.85 2.93 2.93 2.64 2.638
Quick Ratio 1.94 2.71 2.71 2.28 2.28 2.70 2.70 1.77 1.77 2.22 2.22 2.12 2.12 2.14 2.14 1.95 1.95 2.23 2.23 1.98 1.976
Debt/Equity 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.06 0.06 0.06 0.057
Net Debt/Equity -0.12 -0.17 -0.17 -0.09 -0.09 -0.16 -0.16 -0.24 -0.24 -0.13 -0.13 -0.12 -0.12 -0.19 -0.19 -0.15 -0.15 -0.16 -0.16 -0.09 -0.089
Debt/Assets 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.04 0.04 0.042
Debt/EBITDA 0.03 0.03 0.03 0.02 0.02 0.03 0.03 0.04 0.04 0.03 0.03 0.03 0.03 0.02 0.02 0.04 0.03 0.17 0.17 0.17 0.166
Net Debt/EBITDA -0.33 -0.53 -0.53 -0.29 -0.29 -0.59 -0.63 -0.92 -0.87 -0.45 -0.40 -0.34 -0.32 -0.53 -0.52 -0.42 -0.41 -0.48 -0.47 -0.26 -0.258
Interest Coverage 113.14 132.78 174.54 321.57 412.76 306.25 170.47 159.47 170.56 144.70 175.13 155.50 165.60 110.69 74.98 58.36 48.43 56.18 66.59 86.52 86.515
Equity Multiplier 1.26 1.21 1.21 1.24 1.24 1.23 1.23 1.38 1.38 1.27 1.27 1.30 1.30 1.30 1.30 1.32 1.32 1.31 1.31 1.36 1.360
Cash Ratio snapshot only 0.469
Debt Service Coverage snapshot only 97.263
Cash to Debt snapshot only 2.555
FCF to Debt snapshot only 2.183
Defensive Interval snapshot only 632.0 days
Efficiency & Turnover
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Asset Turnover 0.82 0.80 0.82 0.84 0.89 0.83 0.86 0.86 0.87 0.88 0.91 0.90 0.93 0.97 0.98 0.95 0.98 0.94 0.98 0.98 0.976
Inventory Turnover 1.11 1.10 1.12 1.14 1.28 1.33 1.44 1.31 1.27 1.33 1.36 1.62 1.64 1.66 1.62 1.30 1.31 1.87 1.90 1.68 1.676
Receivables Turnover 3.87 3.93 4.04 3.74 3.97 3.54 3.67 3.60 3.67 3.36 3.48 3.65 3.76 4.16 4.20 3.78 3.91 3.99 4.17 3.59 3.591
Payables Turnover 1.90 2.28 2.34 2.53 2.84 2.97 3.21 2.80 2.73 2.72 2.79 3.01 3.05 3.47 3.37 2.46 2.47 3.64 3.71 3.09 3.092
DSO 94 93 90 98 92 103 99 101 99 109 105 100 97 88 87 97 93 92 87 102 101.6 days
DIO 329 333 325 321 286 274 254 279 287 275 268 225 222 220 226 280 278 195 192 218 217.8 days
DPO 192 160 156 144 129 123 114 130 134 134 131 121 120 105 108 149 147 100 98 118 118.0 days
Cash Conversion Cycle 231 266 259 274 249 254 239 250 252 249 242 204 199 202 204 229 224 187 181 201 201.4 days
Fixed Asset Turnover snapshot only 2.617
Operating Cycle snapshot only 319.4 days
Cash Velocity snapshot only 8.204
Capital Intensity snapshot only 1.129
Growth (YoY)
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Revenue 11.8% 15.0% 14.2% 15.4% 19.1% 14.4% 15.4% 14.0% 9.3% 10.2% 9.9% 12.5% 13.6% 15.1% 12.3% 9.0% 9.5% 9.4% 13.4% 18.9% 18.86%
Net Income 35.7% 27.2% 15.5% 9.0% 5.0% -4.4% -14.4% -17.5% -12.9% -2.1% 19.2% 38.8% 37.4% 32.5% 22.0% 12.8% 8.9% 11.3% 13.0% 14.7% 14.73%
EPS 37.0% 28.4% 15.5% 9.4% 6.3% -3.2% -13.3% -15.3% -11.4% -0.4% 21.3% 38.7% 37.5% 33.1% 22.7% 13.8% 9.7% 11.7% 13.3% 14.7% 14.69%
FCF 23.1% 18.4% 40.0% 85.6% 45.3% 5.0% -22.5% -22.5% -35.1% -25.8% -14.0% 53.1% 1.3% 1.7% 2.1% 89.8% 62.7% 26.8% 17.0% -17.0% -17.01%
EBITDA 25.1% 14.4% 10.6% 2.0% 0.5% -6.0% -13.0% -15.6% -11.1% 1.5% 21.1% 42.5% 40.8% 32.1% 19.8% 7.8% 4.9% 7.7% 10.0% 15.7% 15.72%
Op. Income 34.3% 16.0% 8.1% -9.5% -8.8% -10.4% -14.1% -11.1% -4.0% 6.2% 27.0% 44.3% 66.3% 1.0% 75.7% 64.1% 45.7% -5.2% 20.8% 44.2% 44.21%
OCF Growth snapshot only 12.93%
Asset Growth snapshot only 22.73%
Equity Growth snapshot only 19.44%
Debt Growth snapshot only 4.49%
Shares Change snapshot only 0.04%
Dividend Growth snapshot only -53.95%
Growth (CAGR)
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Revenue 3Y 10.5% 12.5% 15.4% 17.7% 18.1% 16.9% 15.5% 13.5% 13.3% 13.2% 13.1% 13.9% 14.0% 13.2% 12.5% 11.8% 10.8% 11.5% 11.8% 13.4% 13.37%
Revenue 5Y 10.1% 10.4% 10.3% 10.5% 11.8% 11.8% 12.1% 11.9% 11.9% 12.4% 14.3% 15.9% 15.4% 15.2% 13.7% 12.4% 12.6% 12.8% 13.0% 13.9% 13.88%
EPS 3Y 13.0% 14.9% 23.1% 23.1% 22.6% 21.2% 13.8% 9.3% 8.9% 7.3% 6.7% 8.7% 9.0% 8.7% 8.9% 10.2% 10.1% 14.0% 19.0% 21.9% 21.88%
EPS 5Y 9.5% 8.8% 7.9% 7.5% 8.8% 7.5% 5.4% 5.6% 6.3% 7.9% 14.5% 17.0% 17.5% 18.8% 17.0% 15.6% 14.2% 13.0% 11.1% 10.9% 10.91%
Net Income 3Y 12.3% 14.2% 22.4% 22.6% 21.7% 20.3% 13.0% 7.9% 7.5% 6.0% 5.7% 7.7% 7.9% 7.4% 7.6% 8.9% 9.2% 13.0% 18.0% 21.6% 21.55%
Net Income 5Y 9.1% 8.4% 7.5% 7.1% 8.2% 6.9% 4.8% 4.6% 5.3% 6.9% 13.4% 16.1% 16.6% 17.7% 16.0% 14.5% 13.2% 11.9% 10.2% 10.1% 10.06%
EBITDA 3Y 13.3% 14.4% 21.1% 21.2% 20.5% 17.8% 10.3% 4.6% 3.8% 3.0% 5.3% 7.0% 8.0% 8.0% 8.1% 9.0% 9.5% 13.0% 16.9% 21.1% 21.12%
EBITDA 5Y 10.5% 9.9% 9.2% 8.2% 9.2% 7.6% 5.8% 5.3% 5.4% 7.4% 13.3% 16.4% 17.0% 17.0% 14.3% 11.9% 10.6% 9.2% 9.0% 8.9% 8.87%
Gross Profit 3Y 7.9% 9.0% 12.0% 14.6% 15.1% 14.8% 13.5% 12.9% 13.3% 13.0% 12.6% 9.9% 10.2% 10.6% 10.4% 13.0% 13.2% 10.1% 11.5% 13.2% 13.24%
Gross Profit 5Y 9.7% 9.6% 9.3% 8.7% 9.4% 9.2% 9.0% 9.3% 9.5% 10.0% 12.0% 12.5% 12.8% 13.5% 12.8% 13.1% 13.5% 10.9% 11.2% 12.5% 12.55%
Op. Income 3Y 13.0% 13.6% 20.1% 17.8% 17.4% 15.6% 8.7% 5.6% 5.6% 3.3% 5.7% 5.1% 13.4% 24.0% 24.2% 28.2% 32.5% 26.4% 39.2% 50.6% 50.60%
Op. Income 5Y 8.9% 7.6% 7.1% 5.2% 6.6% 5.8% 4.1% 4.1% 4.8% 6.9% 13.6% 15.9% 20.9% 26.9% 23.4% 22.7% 23.3% 16.0% 20.1% 22.4% 22.42%
FCF 3Y 31.0% 1.2% 1.3% 1.2% 1.2% 1.0% 44.4% 23.6% 5.1% -2.6% -2.3% 30.1% 29.0% 28.3% 27.6% 31.1% 34.0% 36.6% 46.4% 34.1% 34.10%
FCF 5Y 26.0% 53.9% 25.2% 12.6% 5.2% -2.5% -0.0% 7.4% 16.2% 54.6% 52.0% 67.6% 72.6% 76.4% 51.9% 40.6% 33.9% 25.9% 27.8% 28.3% 28.25%
OCF 3Y 0.6% 12.2% 12.0% 9.4% 6.8% -2.2% -11.6% -13.1% -23.1% -24.0% -23.7% 5.1% 12.3% 17.7% 21.9% 26.6% 31.3% 44.6% 61.6% 53.8% 53.77%
OCF 5Y 3.5% 4.3% 1.8% -1.5% -4.4% -10.4% -12.4% -9.4% -11.5% -6.8% -8.0% 3.8% 8.4% 11.9% 14.7% 16.1% 17.4% 18.3% 20.3% 23.6% 23.64%
Assets 3Y 15.6% 14.2% 14.2% 14.6% 14.6% 12.8% 12.8% 12.1% 12.1% 6.5% 6.5% 7.1% 7.1% 5.6% 5.6% 7.3% 7.3% 8.4% 8.4% 9.6% 9.57%
Assets 5Y 20.6% 18.6% 18.6% 17.3% 17.3% 15.8% 15.8% 13.8% 13.8% 10.2% 10.2% 11.5% 11.5% 9.1% 9.1% 8.6% 8.6% 9.1% 9.1% 10.2% 10.25%
Equity 3Y 13.6% 14.0% 14.0% 13.3% 13.3% 13.4% 13.4% 9.2% 9.2% 6.1% 6.1% 6.0% 6.0% 3.1% 3.1% 5.1% 5.1% 6.2% 6.2% 10.1% 10.14%
Book Value 3Y 14.3% 14.6% 14.6% 13.7% 14.1% 14.2% 14.2% 10.7% 10.7% 7.5% 7.2% 7.1% 7.1% 4.2% 4.3% 6.3% 6.0% 7.1% 7.1% 10.4% 10.44%
Dividend 3Y -8.8% -14.2% -17.9% -9.8% -6.7% -15.7% -30.4% -30.0% — — — 1.0% — — — 54.2% 16.5% -10.6% -25.2% -22.6% -22.56%
Growth Quality
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Revenue Stability 0.89 0.88 0.89 0.87 0.89 0.92 0.94 0.96 0.97 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.99 0.98 0.979
Earnings Stability 0.41 0.41 0.44 0.51 0.63 0.62 0.58 0.56 0.62 0.67 0.77 0.75 0.79 0.80 0.78 0.75 0.78 0.80 0.78 0.76 0.761
Margin Stability 0.96 0.96 0.96 0.96 0.96 0.96 0.95 0.95 0.95 0.94 0.94 0.94 0.95 0.97 0.97 0.96 0.96 0.96 0.96 0.96 0.957
Rev. Growth Consistency 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Earn. Growth Consistency 1.00 1.00 1.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.000
FCF Positive Streak 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Earnings Persistence 0.86 0.89 0.94 0.96 0.98 0.98 0.94 0.93 0.95 0.99 0.92 0.84 0.85 0.87 0.91 0.95 0.96 0.95 0.95 0.94 0.941
Earnings Smoothness 0.70 0.76 0.86 0.91 0.95 0.95 0.84 0.81 0.86 0.98 0.82 0.67 0.69 0.72 0.80 0.88 0.91 0.89 0.88 0.86 0.863
ROE Trend 0.04 0.04 0.02 0.02 0.01 -0.01 -0.04 -0.04 -0.04 -0.01 0.02 0.03 0.04 0.05 0.05 0.04 0.03 0.01 0.01 -0.00 -0.003
Gross Margin Trend 0.01 0.00 0.00 -0.02 -0.03 -0.04 -0.05 -0.03 -0.01 0.01 0.02 -0.04 -0.03 -0.03 -0.01 0.05 0.05 -0.03 -0.03 -0.00 -0.002
FCF Margin Trend 0.03 0.04 0.04 0.04 0.02 -0.01 -0.02 -0.01 -0.03 -0.03 -0.03 0.01 0.03 0.06 0.08 0.07 0.08 0.05 0.05 -0.01 -0.013
Sustainable Growth Rate 21.5% 20.3% 21.0% 20.8% 20.8% 18.2% 17.1% 17.1% 18.7% 18.6% 20.8% 18.9% 15.3% 11.0% 7.1% 9.6% 11.8% 16.0% 18.8% 19.1% 19.09%
Internal Growth Rate 20.4% 19.7% 20.5% 19.9% 20.0% 17.5% 16.3% 14.9% 16.6% 17.5% 19.9% 16.4% 12.9% 9.3% 5.9% 7.9% 9.9% 13.9% 16.8% 16.6% 16.57%
Cash Flow Quality
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
OCF/Net Income 0.55 0.57 0.60 0.61 0.60 0.52 0.44 0.46 0.32 0.30 0.28 0.49 0.62 0.75 0.87 0.95 1.04 1.09 1.14 0.94 0.939
FCF/OCF 0.56 0.64 0.70 0.70 0.71 0.77 0.86 0.86 1.00 1.00 1.00 0.90 0.86 0.83 0.81 0.78 0.76 0.65 0.64 0.57 0.573
FCF/Net Income snapshot only 0.538
OCF/EBITDA snapshot only 0.633
CapEx/Revenue 5.6% 4.7% 4.0% 3.9% 3.5% 2.3% 1.0% 1.0% 0.0% 0.0% 0.0% 0.9% 1.8% 2.5% 3.4% 4.2% 5.0% 7.5% 8.0% 7.8% 7.77%
CapEx/Depreciation snapshot only 2.447
Accruals Ratio 0.09 0.08 0.07 0.07 0.07 0.08 0.08 0.07 0.10 0.10 0.12 0.09 0.07 0.05 0.02 0.01 -0.01 -0.02 -0.03 0.01 0.012
Sloan Accruals snapshot only 0.054
Cash Flow Adequacy snapshot only 1.446
Earnings Quality Score snapshot only 0.750
Dividends & Buybacks
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Dividend Yield 0.4% 0.4% 0.3% 0.4% 0.4% 0.3% 0.1% 0.1% 0.0% 0.0% 0.0% 0.6% 1.1% 1.2% 1.8% 1.8% 1.6% 1.1% 0.8% 0.7% 1.70%
Dividend/Share $6.02 $5.43 $4.79 $4.81 $4.84 $3.22 $1.60 $1.63 $0.00 $0.00 $0.00 $12.74 $25.51 $38.40 $51.26 $45.56 $39.67 $26.83 $20.97 $20.98 $60.00
Payout Ratio 11.5% 10.0% 8.6% 8.7% 8.7% 6.1% 3.3% 3.5% 0.0% 0.0% 0.0% 19.7% 37.6% 55.0% 71.5% 61.8% 53.3% 34.4% 25.8% 24.8% 24.82%
FCF Payout Ratio 37.1% 27.4% 20.4% 20.5% 20.3% 15.3% 8.7% 8.7% 0.0% 0.0% 0.0% 44.5% 71.0% 88.7% 1.0% 83.1% 67.4% 48.7% 35.4% 46.2% 46.15%
Total Payout Ratio 16.5% 19.6% 22.7% 23.0% 28.2% 21.7% 14.9% 15.6% 0.0% 0.0% 0.0% 31.6% 60.4% 88.4% 1.1% 1.0% 93.1% 62.5% 51.8% 41.5% 41.46%
Div. Increase Streak 0 0 0 0 0 0 0 0 — — — 0 0 0 0 1 1 0 0 0 0
Chowder Number -0.25 -0.38 -0.45 -0.27 -0.20 -0.41 -0.67 -0.67 — — — 6.82 — — — 2.56 0.56 -0.29 -0.58 -0.53 -0.532
Buyback Yield 0.2% 0.4% 0.5% 0.7% 0.9% 0.7% 0.5% 0.5% 0.0% 0.0% 0.0% 0.4% 0.7% 0.7% 1.1% 1.2% 1.2% 0.9% 0.8% 0.5% 0.50%
Net Buyback Yield 0.2% 0.4% 0.5% 0.7% 0.9% 0.7% 0.5% 0.5% 0.0% 0.0% 0.0% 0.4% 0.7% 0.7% 1.1% 1.2% 1.2% 0.9% 0.8% 0.5% 0.50%
Total Shareholder Return 0.6% 0.7% 0.9% 1.1% 1.3% 0.9% 0.6% 0.6% 0.0% 0.0% 0.0% 0.9% 1.8% 2.0% 2.8% 2.9% 2.7% 2.0% 1.5% 1.2% 1.25%
DuPont Factors
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Tax Burden (NI/EBT) 0.74 0.76 0.77 0.78 0.78 0.79 0.78 0.79 0.78 0.76 0.74 0.73 0.73 0.74 0.75 0.77 0.78 0.78 0.78 0.77 0.767
Interest Burden (EBT/EBIT) 0.99 0.99 0.99 0.99 0.99 0.99 0.98 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.98 0.98 0.98 0.98 0.99 0.988
EBIT Margin 0.32 0.30 0.30 0.28 0.26 0.24 0.22 0.20 0.21 0.22 0.25 0.27 0.27 0.27 0.27 0.26 0.26 0.26 0.26 0.26 0.256
Asset Turnover 0.82 0.80 0.82 0.84 0.89 0.83 0.86 0.86 0.87 0.88 0.91 0.90 0.93 0.97 0.98 0.95 0.98 0.94 0.98 0.98 0.976
Equity Multiplier 1.27 1.23 1.23 1.25 1.25 1.22 1.22 1.31 1.31 1.25 1.25 1.34 1.34 1.29 1.29 1.31 1.31 1.31 1.31 1.34 1.343
Per Share
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
EPS (Diluted TTM) $52.39 $54.38 $55.51 $55.13 $55.70 $52.61 $48.15 $46.70 $49.36 $52.40 $58.39 $64.78 $67.85 $69.76 $71.67 $73.71 $74.41 $77.91 $81.21 $84.54 $84.54
Book Value/Share $230.86 $258.85 $258.69 $252.50 $254.80 $281.19 $281.25 $269.07 $269.07 $276.34 $276.35 $283.14 $283.48 $293.16 $293.52 $303.53 $303.26 $345.28 $345.38 $362.40 $362.35
Tangible Book/Share $230.03 $258.10 $257.93 $251.80 $254.09 $280.56 $280.61 $268.45 $268.45 $275.62 $275.64 $281.98 $282.31 $292.10 $292.45 $299.80 $299.54 $341.98 $342.08 $359.08 $359.08
Revenue/Share $225.55 $238.57 $245.28 $254.03 $272.18 $276.27 $286.77 $297.24 $302.80 $309.77 $320.37 $334.04 $344.29 $358.05 $361.76 $367.37 $379.67 $393.08 $411.50 $436.52 $462.33
FCF/Share $16.22 $19.83 $23.43 $23.50 $23.88 $21.08 $18.39 $18.70 $15.77 $15.92 $16.07 $28.61 $35.94 $43.29 $50.50 $54.80 $58.89 $55.08 $59.23 $45.46 $8.84
OCF/Share $28.75 $31.06 $33.34 $33.46 $33.48 $27.33 $21.29 $21.66 $15.77 $15.92 $16.07 $31.63 $42.00 $52.41 $62.67 $70.32 $77.70 $84.73 $92.20 $79.38 $22.73
Cash/Share $29.14 $45.50 $45.47 $25.39 $25.62 $48.21 $48.22 $67.00 $67.00 $38.23 $38.23 $36.47 $36.52 $59.15 $59.22 $49.25 $49.20 $75.22 $75.25 $53.20 $0.00
EBITDA/Share $80.23 $81.25 $82.46 $80.83 $81.70 $77.33 $72.73 $70.04 $73.89 $79.82 $89.60 $99.73 $104.12 $105.96 $107.97 $108.43 $110.00 $114.54 $119.05 $125.43 $125.43
Debt/Share $2.42 $2.07 $2.07 $1.94 $1.95 $2.22 $2.22 $2.83 $2.83 $2.62 $2.62 $2.80 $2.80 $2.61 $2.62 $3.80 $3.79 $19.68 $19.68 $20.83 $20.83
Net Debt/Share $-26.73 $-43.42 $-43.40 $-23.45 $-23.67 $-45.99 $-46.00 $-64.17 $-64.17 $-35.61 $-35.61 $-33.67 $-33.71 $-56.54 $-56.61 $-45.45 $-45.41 $-55.55 $-55.56 $-32.38 $-32.38
Academic Models
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Altman Z-Score — — — — — — — — — — — — — — — — — — — — 15.998
Altman Z-Prime snapshot only 28.916
Piotroski F-Score 7 7 6 7 7 5 5 5 5 5 6 6 8 7 7 6 7 6 7 5 5
Beneish M-Score -1.90 -1.90 -1.98 -1.72 -1.71 -1.78 -1.73 -2.19 -2.07 -1.87 -1.77 -1.55 -1.87 -2.37 -2.49 -2.49 -2.43 -1.76 -2.14 -1.81 -1.812
Ohlson O-Score snapshot only -11.904
ROIC (Greenblatt) snapshot only 31.65%
Net-Net WC snapshot only $168.73
EVA snapshot only $14685374227.13
Credit
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Credit Rating snapshot only AA+
Credit Score 95.76 95.61 95.53 95.45 95.83 95.64 96.20 95.56 95.53 95.34 95.06 95.24 95.36 94.99 95.19 94.83 94.80 94.62 94.61 94.68 94.677
Credit Grade snapshot only 2
Credit Trend snapshot only -0.157
Implied Spread (bps) snapshot only 65.000
Industry Credit Rank snapshot only 85
Sector Credit Rank snapshot only 91

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms